Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Analysts retain buy on Sun Pharma as USFDA clears Mohali, Halol unit resolution key

      CLSA says Mohali plant clearance is a significant positive development for the company and shows progress on regulatory issues. Clearance makes a large oral solid dosage site available to de-risk existing sites.

    • Buy, sell, hold: 8 key largecap stocks to watch out today

      CLSA remains negative on cement sector as it believes 2017 will be a lacklustre year for the sector. It has negative ratings on all cement company except UltraTech Cement that is its only preferred name in the sector.

    • Sun Pharma can touch Rs 900, says Vijay Chopra

      Vijay Chopra of enochventures.com feels that Sun Pharmaceutical Industries can touch Rs 900.

    • Bullish on Reliance, expect to touch Rs 1600: Rajen Shah

      In an interview to CNBC-TV18, Rajen Shah, Chief Investment Advisor at Tradebulls Group shared his readings and outlook on specific stocks and sectors.

    • Buy Mahindra and Mahindra, Infosys, Sun Pharma: VK Sharma

      VK Sharma of HDFC Securities recommends buying Mahindra and Mahindra, Infosys, Sun Pharma and advises Bull Spread in Tata Steel.

    • Buy Gujarat Gas, Mcleod Russel, Sun Pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com advises buying Gujarat Gas, Mcleod Russel (India) and Sun Pharmaceutical Industries.

    • Buy Federal Bank, Hindalco, Sun Pharma: Yogesh Mehta

      Yogesh Mehta of Motilal Oswal suggests buying Federal Bank, Hindalco Industries and Sun Pharmaceutical Industries.

    • Here are Sanjiv Bhasin's top trading ideas

      In an interview to CNBC-TV18's Latha Venkatesh, Sonia Shenoy and Anuj Singhal, Sanjiv Bhasin of IIFL shared his reading and outlook on the market and also gave recommendations on various stocks.

    • Here‘s why Deutsche Bank is upbeat on pharmaceutical sector

      Easing regulatory concerns and actions by the US Food and Drug Administration (FDA) will help the sector and improve investor sentiment, Deutsche Bank said in a report.

    • Buy, sell, hold: 8 stocks to watch out for your portfolio

      Morgan Stanley feels any interest in Axis Bank will be based on its retail franchise as it is one of the few banks with a strong retail deposit franchise.

    • Exit Orchid Pharma; pick Lupin, Sun Pharma: Avinash Gorakshakar

      Avinash Gorakshakar, Market Expert advises exiting Orchid Pharma and one can prefer Lupin and Sun Pharmaceutical Industries.

    • Buy, sell, hold: 7 stocks analysts are watching out

      Goldman Sachs says Kotak Mahindra Bank may outperform on improving growth prospects & top quartile EPS growth. Lending book is likely to grow at 25 percent hereon, it feels.

    • Buy Bharat Financial, Sun Pharma; sell Bharti Infratel: Thakkar

      Mitessh Thakkar of miteshthacker.com is of the view that one can buy Bharat Financial Inclusion and Sun Pharmaceutical Industries and sell Bharti Infratel.

    • Bull's Eye: Buy Sun Pharma, Siemens, Pidilite, Just Dial, DHFL

      Sumeet Jain of Destimoney Securities advises buying Castrol India with a target of Rs 454.

    • Here is why SP Tulsian is bullish on Petronet LNG

      SP Tulsian of sptulsian.com, explains why he is bullish on Petronet LNG. He also discusses key pharma sector likes Cadila Healthcare, Divis Laboratories and Aurobindo Pharma.

    • Buy Petronet LNG, SRF, Sun Pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com advises buying Petronet LNG, SRF and Sun Pharma.

    • Buy Escorts; sell NCC, Sun Pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Escorts and sell NCC and Sun Pharma.

    • Here are SP Tulsian's stock ideas

      In an interview to CNBC-TV18's Latha Venkatesh, Sonia Shenoy and Anuj Singhal, SP Tulsian of sptulsian.com shared his reading and outlook on the market and also gave recommendations on various stocks.

    • Stay invested in Sun Pharma: Sharmila Joshi

      According to Sharmila Joshi of sharmilajoshi.com, one may stay invested in Sun Pharma.

    • Buy Reliance Infrastructure, Sun Pharma: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com recommends buying Reliance Infrastructure and Sun Pharma.

    • Hold Sun Pharma, says Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may hold Sun Pharmaceutical Industries.

    • Buy, sell, hold: 8 stocks to watch out post Q3 results

      CLSA says Power Grid's best is yet to come in terms of capitalisation and estimates 50 percent rise in regulated equity over FY16-19. The brokerage house has reiterated buy call on the stock, with increased target at Rs 238 from Rs 225 as it feels valuations are inexpensive despite a 39 percent rally in one year.

    • Buy Sun Pharma, Exide Industries, Tata Motors: Yogesh Mehta

      Yogesh Mehta of Motilal Oswal is of the view that one can buy Sun Pharmaceutical Industries, Exide Industries and Tata Motors.

    • Buy Sun Pharma; sell MRF, Tata Motors DVR: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com suggests buying Sun Pharmaceutical Industries and advises selling MRF and Tata Motors DVR.

    • Buy, sell, hold: 7 stocks analysts are watching out

      Morgan Stanley also says Jubilant Foodworks' earnings are ahead of estimates and there was impressive cost control. It is best placed to capitalise on urban consumption recovery, it feels. The research firm is overweight on the Stock, with a target price at Rs 1,230.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347